Meeting
2023 ASCO Annual Meeting
Response to immune checkpoint inhibitor (ICI) rechallenge in patients with metastatic renal cell carcinoma who progressed on prior ICI: A systematic review and meta-analysis.
Authors
Garima Gupta
University of Kentucky, Lexington, KY
Garima Gupta , Donglin Yan , Zin Myint
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4547)
DOI
10.1200/JCO.2023.41.16_suppl.4547
Abstract #
4547
Poster Bd #
39
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
A framework for living evidence synthesis in cancer: Living, interactive network meta-analysis for first-line treatment of metastatic renal cell carcinoma (mRCC).
First Author: Irbaz Bin Riaz
Poster
2022 ASCO Annual Meeting
Characterization of the microbial resistome in a prospective trial of CBM588 in metastatic renal cell carcinoma (mRCC) offers mechanism for interplay between antibiotic (abx) use and immune checkpoint inhibitor (ICI) activity.
First Author: Nazli Dizman
Poster
2021 Genitourinary Cancers Symposium
Salvage nivolumab plus ipilimumab after prior PD-1/PD-L1 inhibitor treatment in metastatic renal cell carcinoma: A meta-analysis.
First Author: Ming Yin
Poster
2020 ASCO Virtual Scientific Program
Comparative efficacy of chemoimmunotherapy versus immunotherapy alone in the front-line treatment of advanced non-small cell lung cancer: A systematic review and network meta-analysis.
First Author: Ranjan Pathak